Bio Blast Pharma Ltd. (Nasdaq: ORPN) reported positive results from a HOPEMD Phase 2 clinical study in patients with oculopharyngeal muscular dystrophy. The stock price more than doubled by leaping $2.69 to $5.33.
Bio Blast Pharma reports upbeat study results
March 16, 2016 at 14:07 PM EDT
